Sort
30,917 grants matching “tumor microenvironment”
Development of Programmable mRNA Circuits for Melanoma Immunotherapy
$399,508Ryan Sowell · Strand Therapeutics Inc · R43 · FY2021 · CA
A novel targeted antibody therapeutic to treat ovarian cancer
$399,478Reiner Laus · Trio Pharmaceuticals Inc. · R43 · FY2024 · CA
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
$399,474Raymond Nelson Dubois · Arizona State University-Tempe Campus · R01 · FY2014 · CA
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia
$399,447Andrea Bonetto · University Of Colorado Denver · R01 · FY2025 · AR
Feasibility study of a novel NK and CD8 T cells stimulating agent
$399,444Robert H Pierce · Cancure, Llc · R43 · FY2025 · CA
Novel Anti-CCR8 VHH for the Treatment of NSCLC
$399,424Mauro Mileni · Abilita Bio, Inc. · R43 · FY2023 · CA
Hyaluronan Receptors in Prostate Cancer Progression
$399,378James B. McCarthy · University Of Minnesota · R01 · FY2012 · CA
Mechanisms of cellular crosstalk in tumor-promoting niche formation
$399,369Naoki Oshimori · Oregon Health & Science University · R01 · FY2024 · CA
Transfer of microRNA regulators from glioblastoma to brain microenvironment
$399,348Xandra Owens Breakefield · Massachusetts General Hospital · U19 · FY2014 · CA
Development of a Novel Therapeutic Transporter to Treat Metastatic Cancers
$399,346Richard L. Klemke · Cytonus Therapeutics, Inc. · R41 · FY2020 · CA
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
$399,338Daniela Annenelie Bota · University Of California-Irvine · R01 · FY2024 · NS
Development of Immunostimulatory Virotherapy Without Neurotoxicity for the Treatment of Brain Malignancies
$399,335Matthew Stremlau · Implicyte, Inc. · R43 · FY2021 · CA
Off-the-shelf engineered NK cells to treat glioblastoma
$399,314Joe Trebley · Monon Bioventures, Llc · R43 · FY2022 · CA
Understanding PPARgamma signaling in melanoma brain metastasis
$399,305Qing Chen · Wistar Institute · R01 · FY2023 · CA
Augmenting focused ultrasound-mediated drug delivery to brain tumors with vascular normalization
$399,294Richard J Price · University Of Virginia · R21 · FY2024 · CA
Project 3: Systematic characterization of factors controlling breast cancer progression and resistance
$399,288Michael C Bassik · Stanford University · U54 · FY2022 · CA
Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs)
$399,285Amit Praful Khandhar · Hdt Bio Corporation · R43 · FY2021 · CA
Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy
$399,271Jinming Gao · Ut Southwestern Medical Center · R01 · FY2024 · CA
Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy
$399,271Jinming Gao · Ut Southwestern Medical Center · R01 · FY2025 · CA
An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma
$399,256Samuel Hickenlooper · Luminary Therapeutics, Inc. · R43 · FY2024 · CA
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
$399,250Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2022 · FD
Targeting proton-sensing GPR68 as a ferroptosis-based therapy for glioblastoma
$399,214Charles Houston Williams · Proton Bio, Inc. · R43 · FY2024 · CA
Role of Desmoglein 1 in Keratinocyte-Melanocyte Communication and Melanoma
$399,195Kathleen Janee Green · Northwestern University At Chicago · R01 · FY2021 · CA
Shifting the immune infiltrates in osteosarcoma lung metastases with locally targeted CSF-1Ris for combination therapies
$399,187Sandro R. P. Da Rocha · Virginia Commonwealth University · R21 · FY2021 · CA
ATG16L1 isoforms and CRC health disparities
$399,187Paul Dent · Virginia Commonwealth University · R21 · FY2024 · CA